Moreover, the combination of JAK1/2 inhibitors with TKI therapy and the combined use of ALK and STAT3 inhibitors can regulate the immune response and restore the sensitivity of tumor cells to treatment (58), thereby overcoming the resistance driven by AST and improving the treatment outcome. The gene discussed is STAT3; the disease is neoplasm.